OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Current views on lupus in children	142
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	67
Giant cell arteritis: update on pathogenesis and clinical implications	55
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	53
Editorial introduction	45
Current approach to muscle imaging in myositis	41
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	39
Urticarial vasculitis	39
Axial spondyloarthritis guidelines – aiming for maximum impact	37
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden	34
Editorial introductions	29
Osteoporosis epidemiology using international cohorts	29
Optimizing reproductive health management in lupus and Sjogren's syndrome	28
The gut microbiota in spondyloarthritis: an update	27
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	27
Rheumatoid arthritis – the challenge of heterogeneity	26
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	26
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	25
Editorial introductions	24
Updates on translational and clinical research in systemic sclerosis	23
Ribosome dysfunction in osteoarthritis	23
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	21
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	21
Update on gout management: what is old and what is new	19
Defining and managing flares in axial spondyloarthritis	18

Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	18
Editorial introductions	18
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	18
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	17
Editorial introduction	17
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	17
Epidemiology of myositis	16
Animal models of vasculitis	16
Health inequities in the rheumatic diseases of childhood	16
Editorial introductions	16
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	14
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	14
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	14
Gout and the COVID-19 pandemic	14
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	14
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	14
New developments related to lung complications in pediatric rheumatic disease	13
Editorial introductions	13
Editorial introductions	12
Diagnosis and management of primary heart involvement in systemic sclerosis	12
Insights into origins and specificities of autoantibodies in systemic sclerosis	12
Biomarker discovery in psoriatic disease	12
Exploring challenges in the management and treatment of inclusion body myositis	11
Polymyositis: does it really exist as a distinct clinical subset?	11
Emerging biologic therapies for systemic lupus erythematosus	11
Insights into the molecular landscape of osteoarthritis in human tissues	11
Management of postinfectious inflammatory arthritis	11
AI am the future: artificial intelligence in pediatric rheumatology	11
Investigating gout flares: beyond a definition	10
Epidemiology of osteoarthritis: literature update 2022–2023	10
Editorial introduction	10
Heart involvement in systemic sclerosis: emerging concepts	10
Vasculitis and the NLRP3 inflammasome	10
Current management of giant cell arteritis and its complications	9
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	9
The association of Behçet's syndrome with HLA-B51 as understood in 2021	9
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	9
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	9
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	9
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	8
The contribution of endothelial cells to tissue fibrosis	8
Update on streptococcal-associated rheumatic disease	8
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	8
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	8
Animal models in systemic sclerosis: an update	8
Biomarkers in juvenile idiopathic arthritis: towards precision diagnosis and personalized therapy?	7
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	7
Takayasu arteritis	7
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	7
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	7

New therapies in anti-MDA5 antibody-positive dermatomyositis	7
Bone in osteoarthritis: imaging and interventions	7
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	7
Calcinosis in systemic sclerosis	7
Update on muscle imaging in myositis	7
What are mice teaching us about psoriatic arthritis?	7
Osteoarthritis gene therapy in 2022	6
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	6
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	6
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	6
Go or no-go for treat-to-target in axial spondyloarthritis?	6
Epidemiology of systemic vasculitis	6
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	6
Clinical endpoints in myositis: challenges and ways forward	6
Quo vadis reactive arthritis?	6
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	6
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	5
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	5
Metabolic perturbations in systemic sclerosis	5
Contribution of keratinocytes to dermal fibrosis	5
Renal disease in pediatric rheumatology	5
Calcinosis in systemic sclerosis	5
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	5
Recent advances in immunometabolism in rheumatic diseases	5
Should CAR-T cells be used as monotherapy?	5
Rethinking spondyloarthritis: beyond lumping and splitting	5
Updates in juvenile dermatomyositis: pathogenesis and therapy	5
Regulatory T cells and systemic vasculitis	4
Drug therapy in juvenile spondyloarthritis	4
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	4
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	4
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	4
Disease modification in axial spondyloarthritis – still a controversy?	4
Editorial myositis and myopathies	4
Differential diagnosis of necrotizing myopathy	4
Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity	4
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	4
Editorial introduction	4
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	4
Methods for objective assessment of skin involvement in systemic sclerosis	4
Omics studies in Behçet's disease	4
Advances in osteoarthritis imaging	4
Editorial introduction	4
Vaccination updates and special considerations for systemic lupus erythematosus patients	3
Is osteoarthritis a mitochondrial disease? What is the evidence	3
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	3
An update on inflammation in antiphospholipid syndrome	3
An update on topical therapies for psoriasis	3
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	3
Harnessing artificial intelligence to advance insights in systemic sclerosis skin and lung disease	3
Editorial introductions	3
Novel therapies in juvenile idiopathic arthritis	3
Human genetics of Whipple's disease	3
SGLT-2 inhibitors: new horizons for rheumatologists	3
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	3
Understanding psoriatic disease at single-cell resolution: an update	3
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	3
Gastrointestinal manifestations of systemic sclerosis: current approaches and emerging therapies	3
The impact of omics research on our understanding of osteoarthritis and future treatments	3